22 nd Annual Credit Suisse Healthcare Conference. November 12, nd Annual Credit Suisse Healthcare Conference November 12, 2013.
|
|
- Cameron Hoover
- 5 years ago
- Views:
Transcription
1 22 nd Annual Credit Suisse Healthcare Conference November 12,
2 Safe Harbor For Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like anticipate, expect, project, believe, plan, may, estimate, intend and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could differ materially from the expectations and projections expressed or implied by our forward-looking statements. Factors that may cause such differences can be found in our most recent Form 10-K and Forms 10-Q filed or to be filed with the Securities and Exchange Commission under the headings Risk Factors and Safe Harbor for Forward-Looking Statements. Accordingly, you are cautioned not to place undue reliance on any of our forward-looking statements. Except as required by law, we do not intend to update any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which they may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. 2
3 Disclaimers This presentation includes products that have not been approved or cleared by the U.S. Food and Drug Administration and are not available for sale in the U.S. All future product approval and launch dates are based on estimates of completion of regulatory submissions, review and/or approval or clearance, as well as other business considerations. For reconciliations of non-gaap financial measures used in these presentations to the most directly comparable GAAP figures, please refer to the Investor Relations section of our website at 3
4 Our large and diverse portfolio of innovative products Our Mission: Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Interventional Cardiology Cardiac Rhythm Management Neuromodulation Electrophysiology Urology & Women s Health Cardiovascular 2012 Revenue: $7.1B 1 Interventional Cardiology $2.2 Peripheral Interventions $0.8 Cardiac Rhythm Management $1.9 Rhythm Management Endoscopy Advancing science for life TM 1 Represents Boston Scientific s 2012 revenue excluding $122M of revenue from our Neurovascular businesses, which we sold in Peripheral Intervention $0.4 Neuromodulation $0.5 Urology & Women s Health Endoscopy $1.2 MedSurg drives leadership in our served markets $0.1 Electrophysiology
5 Large End Markets Expected to Stabilize 2012A Growth 2013E Growth E Growth E Growth IC (4%) (4%) (2%) (1%) CRV CRM (5%) (3%) (2%) (1%) EP 10% 12% 12% 11% PI 4% 5% 5% 5% Endo 4% 4% 5% 5% MedSurg Uro/WH (3%) 2% 5% 5% Neuromodulation 6% 6% 7% 8% Core Market Total (1%) 0% 2% 2% Adjacencies 30%+ 30%+ 30%+ 30%+ Total Served Market (1%) 1%+ 2%+ 4%+ 5 with Growth Accelerating from Adjacencies Source: BSC Internal Estimates
6 Strategic Imperatives Advancing science for life TM STRENGTHEN Execution to Grow Share EXPAND into High Growth Adjacencies DRIVE Global Expansion FUND the Journey to Fuel Growth DEVELOP Key Capabilities Our People: Engagement, Development, Retention Our Values: Caring, Meaningful Innovation, High Performance, Global Collaboration, Diversity, Winning Spirit to accelerate growth and enhance profitability 6
7 Rhythm management strategy is focused Comprehensive EP Product Offering WATCHMAN Rhythmia Mapping System U.S. cleared and CE Marked. S-ICD System CE Marked. In the U.S., this is an investigational device and not available for use or sale. U.S. approved and CE Marked. Next Gen ICD/ CRT-D System Completed acquisition of Bard Electrophysiology on November 1. Patient Management Device under development. Not available for use or sale worldwide. Next Gen Stim / Ablation Therapies on providing the EP a comprehensive set of solutions 7
8 Strengthening our Cardiovascular pipeline Interventional Cardiology Peripheral Interventions Synergy TM CE Marked. In the U.S., this device is investigational and is not available for use or sale. ilab Polaris Device under development. Not available for use or sale worldwide. Epic TM Iliac SES U.S. approved and CE Marked. Promus PREMIER TM CE Marked. In the U.S., this device is not available for use or sale. Rubicon 18/35 U.S. cleared and CE Marked. OffRoad CE Marked. In the U.S., this device is not available for use or sale. CrossBoss and Stingray CTO System U.S. cleared and CE marked. with meaningful innovation to grow share 8
9 Differentiated pipeline in MedSurg Endoscopy Urology / Women s Health Neuromodulation Flexiva TM TracTip U.S. cleared and CE Marked. WallFlex Transhepatic U.S. cleared and CE Marked. Next Generation Precision Spectra TM Endobronchial Ultrasound Device under development. Not available for use or sale worldwide. StarFire TM Laser Device under development. Not available for use or sale worldwide. Obtryx II TM Device under development. Not available for use or sale worldwide. to expand share and global reach US approved and CE Marked. 9
10 Expanding into new adjacencies Severe Asthma Only device to treat severe asthma 88% reduction in ER visits over five years 1 FDA and CE mark approved Hypertension Over-the-wire balloon with RF electrodes Enhanced patient safety and efficacy CE marked; projected to begin U.S. IDE trial in Q1 2014* Left Atrial Appendage Permanent closure of left atrial appendage Demonstrated stroke risk reduction vs. Warfarin CE Marked; projected FDA approval in 1H 2014* EP / Atrial Fibrillation 2 3D Image and catheter guidance Mapping system designed for faster diagnostics U.S. cleared and CE marked Transcatheter Aortic Valve Replacement Structural Heart (TAVR) REPRISE I complete; REPRISE II enrollment complete CE Marked; projected to begin U.S. IDE trial in 2014* Deep Brain Stimulation (DBS) Treats Parkinson s movement disorders 1 million U.S. adults affected by Parkinson s disease CE Marked; began U.S. pivotal study in 2013 accelerating our growth and leveraging our capabilities 1 Source: Five-year data from the Asthma Intervention Research 2 (AIR2) clinical trial. 2 We do not have an indication to treat Atrial Fibrillation in the US. 10 * Source: BSC Internal Estimates
11 Driving Global Expansion U.S. 53% 2012A Total Company Revenue BRIC 4% 2017E Total Company Revenue U.S. 50% BRIC 10% Aligned globally for growth More balanced global portfolio Building new capabilities in Emerging Markets International 43% International 40% Brazil, Russia, India and China (BRIC) growing ~30% International 41% International 41% 11 to Accelerate Growth and Establish New Capabilities Source: BSC Internal Estimates
12 Operating income improvement initiatives Gross Margin Improvements Operating Expense Improvements Reduce Product Cost Improve Portfolio Health New Products with Accretive Gross Margin Reduce Other Cost of Sales For Example: Emerging Markets Key Areas Include: Finance I/S HR Legal Clinical Trials Product Development Quality Customer Service Key Partners expand operating margins by 600 basis points over time 12
13 Improved Profitability to Drive $6.7B+ Expected Future Capacity for: $6.5B+ Acquisitions: Growth adjacencies Near-term revenue contribution Stock repurchases under $1B program Risk contingencies $0.2B Legal & tax Q Cash on Hand Adjusted Free Cash Flow 1 Estimate through Adjusted Free Cash Flow excludes any potential amounts related to acquisition-, divestiture- and litigation-related items, significant tax audit settlements and restructuring and restructuring-related items. For reconciliations of our non-gaap financial measures, please refer to the Investor Relations section of our website at Continued Strong Free Cash Flow Source: BSC Internal Estimates
14 Projected to return to growth in E E E Operational Revenue* 0.8% - 1.5% Low-single digit Mid-single digit Adjusted EPS* $0.69 to $0.71 (Includes $0.04 of Med Device tax impact) Mid-high single digit growth High-single to low double digit growth Adjusted FCF* Strong cash flow Strong cash flow Strong cash flow *All numbers are Non-GAAP and exclude goodwill and other intangible asset impairment charges, acquisition and divestiture- related net credits, litigation, and restructuring-related charges, discrete tax items and amortization expense. For reconciliations of non-gaap financial measures to the most directly comparable GAAP figures, please refer to the Investor Relations section of our website at with goal of consistent revenue and adjusted earnings growth 14 Source: BSC Internal Estimates
15 Thank You 15
Citi's Global Health Care Conference. February 25, 2013
Citi's Global Health Care Conference February 25, 2013 1 Boston Scientific Citi Global Healthcare Conference, Feb 25, 2013. Refer to appendix to this presentation for certain regulatory and financial disclosures.
More informationCredit Suisse Healthcare Conference. November 11, Dan Brennan, EVP & CFO
Credit Suisse Healthcare Conference November 11, 2014 Dan Brennan, EVP & CFO 1 Safe harbor for forward-looking statements This presentation contains forward-looking statements within the meaning of Section
More informationinvestmnt Conference August 5, 2015 Susie Lisa, CFA Vice President, Investor Relations
investmnt Conference August 5, 2015 Susie Lisa, CFA Vice President, Investor Relations 1 Safe harbor for forward-looking statements and Disclaimers This presentation contains forward-looking statements
More informationBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2014
FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2014 Marlborough, Mass. (October 22, 2014) -- Boston Scientific Corporation (NYSE: BSX) generated sales of
More informationBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2013
FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2013 Fourth Quarter Marks Third Consecutive Quarter of Improved Performance Natick, Mass. (February
More informationJ.P. Morgan 34 th Annual Healthcare Conference January 12, 2016
J.P. Morgan 34 th Annual Healthcare Conference January 12, 2016 Mike Mahoney President and Chief Executive Officer Safe harbor for forward-looking statements This presentation contains forward-looking
More informationBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2017
FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2017 Marlborough, Mass. (February 1, 2018) -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.408
More informationQ Highlights. October 26, 2017
Q3 2017 Highlights October 26, 2017 Safe Harbor for forward-looking statements and Use of Document: Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within
More informationBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2016
FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2016 Marlborough, Mass. (February 2, 2017) -- Boston Scientific Corporation (NYSE: BSX) generated
More informationBernstein s 34 th Annual Strategic Decisions Conference
Bernstein s 34 th Annual Strategic Decisions Conference Mike Mahoney Chairman and Chief Executive Officer Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements
More information35 th Annual JP Morgan Healthcare Conference
35 th Annual JP Morgan Healthcare Conference Mike Mahoney Chairman & CEO J A N U A R Y 10, 2 0 1 7 1 Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within
More informationJP Morgan Conference. Jim Tobin Chief Executive Officer January 14, 2009
JP Morgan Conference Jim Tobin Chief Executive Officer January 14, 2009 Cautionary Statement for Purposes of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995 This presentation
More informationQ Highlights. April 25, 2018
2018 Highlights April 25, 2018 Safe Harbor for Forward-Looking Statements and Use of Document: Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within the
More informationQ Highlights. July 25, 2018
Q2 2018 Highlights July 25, 2018 Safe Harbor for Forward-Looking Statements and Use of Document: Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within
More informationAbbott Reports First-Quarter 2019 Results
News Release Abbott Reports First-Quarter 2019 Results Sales and EPS growth exceed guidance; projects strong full-year outlook Long-term growth drivers including FreeStyle Libre, MitraClip and Alinity
More informationQ Highlights. February 1, 2018
Q4 2017 Highlights February 1, 2018 Safe Harbor for Forward-Looking Statements and Use of Document: Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within
More informationTranscatheter Cardiovascular Therapeutics 2018
Transcatheter Cardiovascular Therapeutics 2018 Jeff Mirviss, SVP & President, Peripheral Interventions Kevin Ballinger, EVP & President, Interventional Cardiology Dr. Ian Meredith, EVP & Global Chief Medical
More informationBOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017
FOR IMMEDIATE RELEASE BOSTON SCIENTIFIC ANNOUNCES PRELIMINARY UNAUDITED SALES FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2017 Marlborough, Mass. (January 9, 2018) -- Boston Scientific Corporation
More informationTranscatheter Cardiovascular Therapeutics Investor Update October 30, 2017
Transcatheter Cardiovascular Therapeutics Investor Update October 30, 2017 Kevin Ballinger Executive Vice President and President, Interventional Cardiology Professor Ian Meredith, A.M. Executive Vice
More informationCredit Suisse 26 th Annual Healthcare Conference. Joe Fitzgerald, EVP and President, Rhythm Management
Credit Suisse 26 th Annual Healthcare Conference Joe Fitzgerald, EVP and President, Rhythm Management 1 Safe Harbor for Forward-Looking Statements and Regulatory Disclaimers This presentation contains
More informationBOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2007
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2007 Natick, MA (April 23, 2007) -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter
More informationQ Highlights. October 24, 2018
Q3 Highlights October 24, Safe Harbor for Forward-Looking Statements and Use of Document: Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within the meaning
More informationAbbott Reports Third-Quarter 2018 Results
News Release Abbott Reports Third-Quarter 2018 Results Third-quarter reported sales growth of 12.1 percent; organic sales growth of 7.8 percent Third-quarter GAAP EPS from continuing operations of $0.31;
More informationBoston Scientific Corporation
March 06, 2015 Boston Scientific Corporation Current Recommendation Prior Recommendation Outperform Date of Last Change 10/16/2011 Current Price (03/05/15) $16.97 Target Price $18.00 NEUTRAL SUMMARY (BSX-NYSE)
More informationAbbott Reports Second-Quarter 2018 Results
News Release Abbott Reports Second-Quarter 2018 Results Second-quarter reported sales growth of 17.0 percent; GAAP EPS from continuing operations of $0.40 Second-quarter organic sales growth of 8.0 percent
More informationShareholders. To Our. Delivering on an Innovation- Based Growth Strategy
To Our Shareholders Daniel J. Starks Chairman, President and Chief Executive Officer Our vision is to transform the treatment of expensive epidemic diseases. We do this by creating cost-effective medical
More informationAbbott Reports First-Quarter 2018 Results
News Release Abbott Reports First-Quarter 2018 Results First-quarter reported sales growth of 16.7 percent; GAAP EPS from continuing operations of $0.23 First-quarter organic sales growth of 6.9 percent
More informationAbbott Reports Fourth-Quarter 2017 Results
News Release Abbott Reports Fourth-Quarter 2017 Results Fourth-quarter reported sales growth of 42.3 percent; comparable operational sales growth of 7.7 percent Numerous new product approvals and launches
More informationPress Information. June 28, 2017
Press Information June 28, 2017 Philips to acquire The Spectranetics Corporation to accelerate expansion in imageguided therapy devices to treat cardiac and peripheral vascular disease Highly complementary
More informationQ Highlights. February 6, 2019
Q4 2018 Highlights February 6, 2019 Safe Harbor for Forward-Looking Statements and Use of Document: Safe Harbor for forward-looking statements: This presentation contains forward-looking statements within
More informationSymetis Transaction Strategic and Financial Highlights. March 30, 2017
Symetis Transaction Strategic and Financial Highlights March 30, 2017 1 Safe Harbor for Forward-Looking Statements This material contains forward-looking statements within the meaning of federal securities
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers Baird Healthcare Conference, September 2017 NASDAQ: NOVT 1 Safe Harbor Statement The statements in this presentation
More informationUBS Healthcare Conference John J. Greisch, President and CEO. May 22, 2017
UBS Healthcare Conference John J. Greisch, President and CEO May 22, 2017 Forward Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities
More information2Q18 Earnings Conference Call. August 2, 2018
2Q18 Earnings Conference Call August 2, 2018 Presentation of Financial Information & Forward-Looking Statements Historical financial and operating data in this presentation reflect the consolidated results
More informationBoston Scientific Corp.
STUDENT RESEARCH Author: Huong Tran Thi Lan Huong.tran@ucdconnect.ie Please see the disclaimer at back of this report for important information. Medical Appliances & Equipment Boston Scientific Corp. Ticker:
More informationFourth Quarter Fiscal Year 2017
Fourth Quarter Fiscal Year 2017 October 25, 2017 J. Michael Bruff Vice President Investor Relations Mike.Bruff@Varian.com This presentation is intended exclusively for investors. It is not intended for
More informationABBOTT PARK, Ill., Jan. 25, 2017 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2016.
Abbott Reports Fourth-Quarter 2016 Results - FOURTH-QUARTER GAAP EPS FROM CONTINUING OPERATIONS OF $0.51; ADJUSTED EPS FROM CONTINUING OPERATIONS OF $0.65 - ISSUES EPS OUTLOOK FOR 2017, REFLECTING DOUBLE-DIGIT
More informationBOSTON SCIENTIFIC CORPORATION
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Í ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December
More informationABBOTT PARK, Ill., July 20, 2016 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2016.
Abbott Reports Second-Quarter 2016 Results - SECOND-QUARTER REPORTED SALES GROWTH OF 3.2 PERCENT; OPERATIONAL SALES GROWTH OF 6.4 PERCENT - SECOND-QUARTER GAAP EPS FROM CONTINUING OPERATIONS OF $0.40;
More informationPlease note that the following presentation contains financial projections and other forward-looking statements that are specific to the date of the
Please note that the following presentation contains financial projections and other forward-looking statements that are specific to the date of the presentation July 16, 2012 and should not be considered
More informationEndo International plc
Endo International plc Q2 2015 Earnings Report August 10, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More informationThird Quarter 2011 Conference Call
Third Quarter 2011 Conference Call 28 October, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including information
More informationZimmer Biomet Reports Second Quarter 2016 Financial Results
July 28, 2016 Zimmer Biomet Reports Second Quarter 2016 Financial Results -- Net Sales of $1.934 billion represent an increase of 65.6% over the prior year period, and an increase of 4.5% on an adjusted
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers Baird Industrial Conference, November 2017 Matthijs Glastra, Chief Executive Officer NASDAQ: NOVT 1 Safe Harbor Statement
More informationA Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers
A Trusted Technology Partner to Medical and Advanced Technology Equipment Manufacturers February 2018 Matthijs Glastra, Chief Executive Officer NASDAQ: NOVT 1 Safe Harbor Statement The statements in this
More informationAngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results
AngioDynamics Reports Fiscal 2018 Fourth Quarter and Full-Year Financial Results July 11, 2018 Fiscal 2018 Fourth Quarter Highlights Net sales of $88.3 million, an increase of 1.6% year over year Gross
More informationLazard Capital Markets 9 th Annual Healthcare Conference
Lazard Capital Markets 9 th Annual Healthcare Conference November 14, 2012 Glenn P. Muir Executive VP and CFO 1 Forward-Looking Statements This presentation contains forward-looking information that involves
More informationBOSTON SCIENTIFIC CORPORATION
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Í ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December
More information1H 2012 Financial Results & Business Update. August 2012
1H 2012 Financial Results & Business Update August 2012 Content 1H 2012 Financial Results Business Update Long-Term Plans Appendix - financial statement 1 Financial Summary 1H 2012 Highlights Key Financial
More informationAngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results
July 18, 2017 AngioDynamics Reports Fiscal 2017 Fourth Quarter and Full-Year Results Company posts record full-year adjusted EPS and Free Cash Flow and issues FY2018 Financial Guidance Q4 net sales of
More informationSecond Quarter 2018 Earnings Results
Second Quarter 2018 Earnings Results August 1, 2018 Finn, VNS Therapy Patient Safe Harbor Certain statements in this presentation, other than purely historical information, are forward-looking statements
More informationJ.P. MORGAN HEALTHCARE CONFERENCE. Robert Abernathy Chairman and CEO
J.P. MORGAN HEALTHCARE CONFERENCE Robert Abernathy Chairman and CEO OVERVIEW FORWARD-LOOKING INFORMATION Certain matters in this presentation and conference call, including our 2016 outlook, expectations
More informationJ.P. MORGAN HEALTHCARE CONFERENCE. Joe Woody Chief Executive Officer
J.P. MORGAN HEALTHCARE CONFERENCE Joe Woody Chief Executive Officer 0 OVERVIEW FORWARD-LOOKING INFORMATION Certain matters in this presentation and webcast, including our outlook, expectations and planning
More information2018 SECOND QUARTER FINANCIAL RESULTS
2018 SECOND QUARTER FINANCIAL RESULTS July 30, 2018 0 SAFE HARBOR STATEMENT The 2018 second quarter news release, conference call webcast, and the following slides contain forward-looking statements. The
More informationAbbott Reports First-Quarter 2013 Results
PRESS RELEASE Abbott Reports First-Quarter 2013 Results First-Quarter Ongoing EPS of $0.42 (GAAP EPS of $0.34) Company Confirms Full-Year 2013 EPS Guidance April 17, 2013 Abbott Park, Illinois (NYSE: ABT)
More informationFinancial Outlook. Edwards Delivers Outstanding Financial Performance. Edwards Lifesciences 2017 Investor Conference 12/7/17
Financial Outlook Scott B. Ullem Chief Financial Officer Edwards Delivers Outstanding Financial Performance EXCEPTIONAL REVENUE GROWTH STRONG PROFITABILITY LONG-TERM SHAREHOLDER RETURNS ROBUST CASH FLOW
More information4Q18 Earnings Conference Call
4Q18 Earnings Conference Call February 21, 2019 ITGR: 4Q18 Earnings Conference Call / February 21, 2019 / Page 1 Presentation of Financial Information & Forward-Looking Statements Historical financial
More informationEDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS. IRVINE, Calif., October 23, 2018 Edwards Lifesciences Corporation (NYSE: EW), the global leader in
Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact:
More informationCantel Medical Reports Financial Results for its First Quarter Fiscal Year 2019
Cantel Medical Reports Financial Results for its First Quarter Fiscal Year 2019 November 29, 2018 Medical segment leads with strong double-digit growth - Net sales of $225.6M, up 6.0%, with organic sales
More informationEDWARDS LIFESCIENCES REPORTS FOURTH QUARTER RESULTS
Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Sarah Huoh, 949-250-5070 Investor Contact:
More informationJ.P. MORGAN HEALTHCARE CONFERENCE January 10, 2017
J.P. MORGAN HEALTHCARE CONFERENCE January 10, 2017 Forward Looking Statements Statements in this presentation that are not strictly historical, including any statements regarding events or developments
More informationAccelerating Healthcare
Accelerating Healthcare Ingo Bank, CFO Philips Healthcare Name Jefferies Global Healthcare Conference, New York June 4 th, 203 Important information Forward-looking statements This document and the related
More informationMEDTRONIC, INC. REVENUE BY OPERATING SEGMENT - WORLD WIDE (Unaudited)
REVENUE BY OPERATING SEGMENT - WORLD WIDE ($ millions) 1 2 3 4 1 2 3 4 FY09 FY09 FY09 FY09 FY09 FY10 FY10 FY10 FY10 FY10 QTR 1 QTR 2 QTR 3 QTR 4 Total QTR 1 QTR 2 QTR 3 QTR 4 Total REPORTED REVENUE : CARDIAC
More informationCONSOLIDATED FINANCIAL STATEMENTS
FINANCIAL TABLE OF CONTENTS 2 Management s discussion and analysis of financial condition and results of operations 23 Consolidated statements of operations 2003 CONSOLIDATED FINANCIAL STATEMENTS 24 Consolidated
More informationMEDTRONIC, INC. REVENUE BY OPERATING SEGMENT - WORLD WIDE (Unaudited)
REVENUE BY OPERATING SEGMENT - WORLD WIDE ($ millions) 1 2 3 4 1 2 3 4 FY09 FY09 FY09 FY09 FY09 FY10 FY10 FY10 FY10 FY10 QTR 1 QTR 2 QTR 3 QTR 4 Total QTR 1 QTR 2 QTR 3 QTR 4 Total REPORTED REVENUE : CARDIAC
More informationBOSTON SCIENTIFIC 2017 ANNUAL REPORT Annual Report
BOSTON SCIENTIFIC 2017 ANNUAL REPORT 2017 Annual Report LETTER TO SHAREHOLDERS FROM THE CHAIRMAN, PRESIDENT AND CEO BOSTON SCIENTIFIC 2017 ANNUAL REPORT 1 Dear Shareholders: Advancing science for life
More informationSTRYKER. Kevin A. Lobo, President & Chief Executive Officer
STRYKER Kevin A. Lobo, President & Chief Executive Officer January 15, 2014 FORWARD LOOKING STATEMENT Certain statements made in the presentation may contain information that includes or is based on forward-looking
More informationGSI Group to Acquire NDS Surgical Imaging for $82.5 Million
FOR IMMEDIATE RELEASE January 15, 2013 GSI Group to Acquire NDS Surgical Imaging for $82.5 Million NDS is the leading producer of high performance visualization products sold to OEMs in the surgical endoscopy
More informationQ First-quarter highlights. Business segments
Q1 2018 Quarterly report Philips reports Q1 sales of EUR 3.9 billion, with 5% comparable sales growth; net income from continuing operations of EUR 94 million, and Adjusted EBITA margin increased 130 basis
More informationDOUBLE-DIGIT SALES GROWTH DRIVES STRONG FOURTH QUARTER RESULTS FOR EDWARDS LIFESCIENCES
Edwards Lifesciences Corporation One Edwards Way Irvine, CA USA 92614 Phone: 949.250.2500 Fax: 949.250.2525 www.edwards.com FOR IMMEDIATE RELEASE Media Contact: Amanda C. Fowler, 949-250-5070 Investor
More informationPolyOne Investor Presentation KeyBanc 2014 Basic Materials & Packaging Conference Boston, MA September 10, 2014
PolyOne Investor Presentation KeyBanc 2014 Basic Materials & Packaging Conference Boston, MA September 10, 2014 PolyOne Corporation Page 1 Forward-Looking Statements In this presentation, statements that
More informationFourth Quarter and Full Year 2017 Results. March 1, 2018
1 Fourth Quarter and Full Year 2017 Results March 1, 2018 Impax Cautionary Statement Regarding Forward Looking Statements 2 "Safe Harbor" statement under the Private Securities Litigation Reform Act of
More informationAngioDynamics. Second Quarter 2019 Earnings Presentation January 4, 2019
AngioDynamics Second Quarter 2019 Earnings Presentation January 4, 2019 1 Forward-Looking Statements Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within
More informationAcorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016
NEWS RELEASE Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 2/14/2017 AMPYRA (dalfampridine) 4Q 2016 Net Revenue of $132 Million; Full-Year Net Revenue of $493 Million
More informationMicroPort to Acquire Wright s OrthoRecon Business. June 19, 2013
MicroPort to Acquire Wright s OrthoRecon Business June 19, 2013 Forward-Looking Statements This presentation may contain forward-looking statements as defined under U.S. federal securities laws. These
More informationIntuitive Surgical Announces Third Quarter Earnings
Intuitive Surgical Announces Third Quarter Earnings October 18, SUNNYVALE, Calif., Oct. 18, (GLOBE NEWSWIRE) -- Intuitive Surgical, Inc. ( Intuitive ) (Nasdaq: ISRG), a global technology leader in roboticassisted,
More informationMRI INTERVENTIONS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationLABCORP ANNOUNCES 2018 SECOND QUARTER RESULTS AND UPDATES 2018 GUIDANCE
FOR IMMEDIATE RELEASE Contact: Scott Frommer (investors) 336-436-5076 Investor@labcorp.com Pattie Kushner (media) 336-436-8263 Media@labcorp.com LABCORP ANNOUNCES 2018 SECOND QUARTER RESULTS AND UPDATES
More informationConceptus, Inc. Mark M. Sieczkarek President and Chief Executive Officer. Raymond James 32nd Annual Institutional Investors Conference.
Conceptus, Inc. Mark M. Sieczkarek President and Chief Executive Officer Raymond James 32nd Annual Institutional Investors Conference March 9, 2011 Safe Harbor Except for the historical information contained
More informationCompelling Strategic Transaction
ACQUISITION OF DJO GLOBAL November 19, 2018 Forward Looking Statements & Non-GAAP Disclaimer The following information may contain forward-looking statements, including forward-looking statements within
More informationMedtronic Public Limited Company Directors' Report and Financial Statements Financial Year Ended April 29, 2016
Medtronic Public Limited Company Directors' Report and Financial Statements Financial Year Ended April 29, 2016 TABLE OF CONTENTS Directors' Report Independent Auditors' Report Consolidated Profit and
More informationEndo International plc
Endo International plc Q1 2015 Earnings Report May 11, 2015 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private
More informationBOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December
More informationFOURTH QUARTER 2017 EARNINGS CALL FEBRUARY 27, 2018
FOURTH QUARTER 2017 EARNINGS CALL FEBRUARY 27, 2018 0 Agenda and Speakers Joe Woody Chief Executive Officer Halyard Outlook and Update on Divestiture 2018 Priorities Steve Voskuil Chief Financial Officer
More informationSECOND QUARTER 2017 EARNINGS CALL AUGUST 2, 2017
SECOND QUARTER 2017 EARNINGS CALL AUGUST 2, 2017 SECOND QUARTER EARNINGS CALL AGENDA CEO Transition Robert Abernathy Chairman Strategic Vision Joe Woody Chief Executive Officer Second Quarter Results and
More informationOur Transformation Continues. March 21, 2018
Our Transformation Continues March 21, 2018 Disclosure Regarding Forward-Looking Statements Forward-Looking Statements and Factors That May Affect Future Results: Throughout this presentation, we make
More informationINVESTOR PRESENTATION DECEMBER 2018
INVESTOR PRESENTATION DECEMBER 2018 SAFE HARBOR AND NON-GAAP Safe Harbor Statement This presentation contains certain comments that are forwardlooking statements, including sales, GAAP diluted EPS, and
More informationBOSTON SCIENTIFIC CORPORATION (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934, or For the fiscal year ended December
More informationINVESTOR PRESENTATION FEBRUARY 2019
INVESTOR PRESENTATION FEBRUARY 2019 SAFE HARBOR AND NON-GAAP Safe Harbor Statement This presentation contains certain comments that are forwardlooking statements, including sales, GAAP diluted EPS, and
More informationToshihiko Osada General Manager, Strategic Planning Department. Corporate Strategy. Terumo Corporation Dec 12, 2016
2 Toshihiko Osada General Manager, Strategic Planning Department Corporate Strategy Outlook: Medtech Industry Global medtech market: Forecast to grow at a CAGR of 5-6% for the next 10 years, with market
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference John J. Greisch, President and CEO January 9, 2018 This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform
More informationEndo International plc
Endo International plc UBS Global Healthcare Conference May 21, 2014 Forward Looking Statements; Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of
More informationStryker. Kevin A. Lobo Chairman and Chief Executive Officer
Stryker Kevin A. Lobo Chairman and Chief Executive Officer Disclaimer Forward-looking statement This presentation contains information that includes or is based on forward-looking statements within the
More informationNet sales $258.2 $234.6 $507.3 $469.6 Cost of goods sold Gross profit
Unaudited Consolidated Statements of Operations Three Months Ended Six Months Ended June 30, June 30, (in millions, except per share data) 2005 2004 2005 2004 Net sales $258.2 $234.6 $507.3 $469.6 Cost
More information2011 Preliminary Results Conference Call. 9 February, SORIN GROUP Presentation 1
2011 Preliminary Results Conference Call 9 February, 2012 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including information
More informationOur Transformation Continues Sidoti NDR May 29-30, 2018
Our Transformation Continues Sidoti NDR May 29-30, 2018 Disclosure Regarding Forward-Looking Statements Forward-Looking Statements and Factors That May Affect Future Results: Throughout this presentation,
More informationWilliam Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles
William Blair 35 th Annual Growth Stock Conference June 9, 2015 Copyright 2014 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
More informationAngioDynamics Reports Fiscal 2014 Second Quarter Financial Results
January 9, 2014 AngioDynamics Reports Fiscal 2014 Second Quarter Financial Results Net sales of $88.6 million GAAP income per share at break-even; Non-GAAP adjusted net income, excluding amortization,
More informationWest Pharmaceutical Services, Inc. Third-Quarter 2018 Analyst Conference Call 9 a.m. Eastern Time, October 25, 2018
West Pharmaceutical Services, Inc. Third-Quarter 2018 Analyst Conference Call 9 a.m. Eastern Time, October 25, 2018 Speakers: Eric M. Green President and Chief Executive Officer Bernard J. Birkett Senior
More informationFiscal 2019 First Quarter Results. October 30, 2018
Fiscal 2019 First Quarter Results October 30, 2018 Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
More information